Cargando…
Late therapeutic intervention with a respiratory syncytial virus L‐protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium
BACKGROUND AND PURPOSE: Effective anti‐respiratory syncytial virus (RSV) agents are still not available for clinical use. Current major targets are virus surface proteins, such as a fusion protein involved in viral entry, but agents effective after RSV infection is established are required. Here we...
Autores principales: | Brookes, Daniel W, Coates, Matthew, Allen, Heather, Daly, Leah, Constant, Samuel, Huang, Song, Hows, Mark, Davis, Amanda, Cass, Lindsey, Ayrton, John, Knowles, Ian, Strong, Pete, Rapeport, Garth, Ito, Kazuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980447/ https://www.ncbi.nlm.nih.gov/pubmed/29579332 http://dx.doi.org/10.1111/bph.14221 |
Ejemplares similares
-
Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study
por: DeVincenzo, John, et al.
Publicado: (2020) -
Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor
por: Coates, Matthew, et al.
Publicado: (2017) -
1335. Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics
por: Cass, Lindsey, et al.
Publicado: (2018) -
An impact of age on respiratory syncytial virus infection in air-liquid-interface culture bronchial epithelium
por: Ito, Kazuhiro, et al.
Publicado: (2023) -
Respiratory Syncytial Virus
por: Fraire, Armando E., et al.
Publicado: (2013)